NASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $3.39 -0.01 (-0.29%) Closing price 09/16/2026 04:00 PM EasternExtended Trading$3.41 +0.02 (+0.62%) As of 09/16/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ardelyx Stock (NASDAQ:ARDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ardelyx alerts:Sign Up Key Stats Today's Range$3.34▼$3.4350-Day Range$3.39▼$5.3852-Week Range$3.34▼$8.40Volume5.38 million shsAverage Volume3.70 million shsMarket Capitalization$844.75 millionP/E RatioN/ADividend YieldN/APrice Target$13.90Consensus RatingModerate Buy Company Overview Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s lead product candidates and marketed medicines are designed to address disorders involving the regulation of phosphate and other substances in the digestive system. Ardelyx markets XPHOZAH (tenapanor) in the United States for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Tenapanor works locally in the gastrointestinal tract by inhibiting the sodium/hydrogen exchanger 3, thereby reducing intestinal phosphate absorption. The company also markets IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation in adults. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx serves the U.S. market through its commercial operations and continues to develop therapies for gastrointestinal and cardiorenal diseases. The company is led by Michael Raab, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Ardelyx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreARDX MarketRank™: Ardelyx scored higher than 64% of companies evaluated by MarketBeat, and ranked 293rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArdelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialArdelyx has a consensus price target of $13.90, representing about 310.0% upside from its current price of $3.39.Amount of Analyst CoverageArdelyx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ardelyx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.20) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -15.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -15.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 4.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.63% of the float of Ardelyx has been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 6.14.Change versus previous monthShort interest in Ardelyx has recently increased by 1.26%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.14 News SentimentArdelyx has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ardelyx this week, compared to 5 articles on an average week.Search Interest10 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows9 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $486,588.00 in company stock.Percentage Held by Insiders5.30% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDX Stock News HeadlinesArdelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 3:00 PM | seekingalpha.comArdelyx (NASDAQ:ARDX) Sets New 1-Year Low - Should You Sell?September 16 at 4:32 AM | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Ardelyx Sees Unusually Large Options Volume (NASDAQ:ARDX)September 16 at 3:41 AM | americanbankingnews.comFinancial Survey: Ardelyx (NASDAQ:ARDX) vs. Dare Bioscience (NASDAQ:DARE)September 14 at 4:30 AM | americanbankingnews.comArdelyx to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comInsider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells 3,982 SharesAugust 26, 2026 | insidertrades.comArdelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats UpAugust 22, 2026 | finance.yahoo.comSee More Headlines ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $5.83 at the beginning of the year. Since then, ARDX shares have decreased by 41.9% and is now trading at $3.39. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.02. The company's quarterly revenue was up 34.3% compared to the same quarter last year. Read the conference call transcript. When did Ardelyx IPO? Ardelyx (ARDX) raised $60 million in an IPO on Wednesday, June 18th 2014. The company issued 4,286,000 shares at a price of $13.00-$15.00 per share. Who are Ardelyx's major shareholders? Top institutional shareholders of Ardelyx include BlackRock Inc. (9.51%), Jupiter Topco LLC (2.13%), AIGH Capital Management LLC (1.30%) and Bank of America Corp DE (0.87%). Insiders that own company stock include David M Mott, Michael Raab, Eric Duane Foster, Justin A Renz, Laura A Williams, Mike Kelliher, Robert Blanks, John E Bishop, Elizabeth A Grammer, James Parker Brady, Susan Hohenleitner, David P Rosenbaum, Joseph James Reilly and Robert Ora Felsch. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/16/2026Morgan Stanley 24th Annual Global Healthcare Conference9/16/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ARDX's financial health is in the Red zone, according to TradeSmith. ARDX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARDX CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees489Year Founded2007Price Target and Rating Average Price Target for Ardelyx$13.90 High Price Target$19.00 Low Price Target$9.00 Potential Upside/Downside+310.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.60 million Net Margins-12.35% Pretax Margin-12.30% Return on Equity-36.00% Return on Assets-10.77% Debt Debt-to-Equity Ratio1.69 Current Ratio3.34 Quick Ratio3.15 Sales & Book Value Annual Sales$407.32 million Price / Sales2.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book4.91Miscellaneous Outstanding Shares249,190,000Free Float235,981,000Market Cap$844.75 million OptionableOptionable Beta0.70 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARDX) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
